{"article_title": "AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP", "article_keywords": ["opposes", "aarp", "yearsaarp", "trade", "drugs", "biologic", "york", "tpp", "12year", "exclusivity", "market", "view"], "article_url": "http://www.law360.com/articles/482976/aarp-opposes-12-year-exclusivity-for-biologic-drugs-in-tpp", "article_text": "AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP\n\nLaw360, New York (October 24, 2013, 4:43 PM ET) -- AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market for 12 years.\n\n\n\nAARP, which represents Americans 50 and older and their families, sent a letter to U.S. Trade Representative Michael Froman saying the U.S. should not sign onto a TPP agreement that binds it to a 12-year market exclusivity period for branded biologic medicines, which can be used to treat diseases like cancer and...\n\nTo view the full article, register now.", "article_metadata": {"description": "AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market for 12 years.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/482976/aarp-opposes-12-year-exclusivity-for-biologic-drugs-in-tpp", "csrf-token": "V+hVqThDO05BbLbN17O7EsuhVQ3b8VdoXXaayHlEU1FyflTSXKB475WcCwBqxLSjpjFRkQ87F2BgLlBab29VqQ==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/482976/aarp-opposes-12-year-exclusivity-for-biologic-drugs-in-tpp", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fe0c15\"", "article_summary": "AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPPLaw360, New York (October 24, 2013, 4:43 PM ET) -- AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market for 12 years.\nAARP, which represents Americans 50 and older and their families, sent a letter to U.S. Trade Representative Michael Froman saying the U.S. should not sign onto a TPP agreement that binds it to a 12-year market exclusivity period for branded biologic medicines, which can be used to treat diseases like cancer and...To view the full article, register now."}